Kyverna Therapeutics (KYTX) Cash from Financing Activities (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Cash from Financing Activities data on file, last reported at -$101000.0 in Q1 2026.

• Quarterly Cash from Financing Activities rose 75.6% year-over-year to -$101000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $141.5 million (up 10580.07% YoY) and the FY2025 annual result came in at $141.2 million, down 58.12% from the prior year.
• Cash from Financing Activities declined to -$101000.0 in Q1 2026, from $140.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $338.0 million in Q1 2024 to a low of -$1.4 million in Q4 2023.
• A 4-year average of $41.3 million and a median of -$144000.0 in 2023 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 234856.25% in 2024, down 102.28% in 2024.
• Tracing KYTX's Cash from Financing Activities over 4 years: stood at -$1.4 million in 2023, then surged by 85.01% to -$215000.0 in 2024, then soared by 65561.86% to $140.7 million in 2025, then tumbled by 100.07% to -$101000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$101000.0 (Q1 2026), $140.7 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.